Ascletis Pharma Inc. (ASCLF) Research

Ascletis Pharma Inc. is a biotechnology firm dedicated to the research, development, production, promotion, and global sale of pharmaceutical products, with a presence in Mainland China and abroad. The company's commercialized portfolio features Ritonavir oral tablets, a pharmacokinetic enhancer for various oral antiviral drugs that target viral proteases, and a crucial ingredient in the approved oral antiviral treatment, Paxlovid. Additionally, Ascletis offers ASCLEVIR and GANOVO for the management of Hepatitis C virus. Ascletis maintains an active pipeline of investigational therapies. This includes ASC22, which is being developed for chronic hepatitis B (CHB) and as a functional cure for human immunodeficiency virus; ASC42, also aimed at achieving a functional cure for chronic hepatitis B; and ASC10 and ASC11, both targeting COVID-19. For metabolic and liver conditions, a series of compounds such as ASC40, ASC41, ASC42, ASC43F FDC, ASC44F FDC, and ASC45F FDC are under development for non-alcoholic steatohepatitis (NASH), with ASC42 also being explored for primary biliary cholangitis. In oncology and other areas, ASC40 is being investigated for recurrent glioblastoma, drug-resistant breast cancer, KRAS mutant non-small cell lung cancer, and acne. Furthermore, ASC61 and ASC63 are candidates for advanced solid tumors, while ASC60 focuses on solid tumors broadly. Established in 2013, Ascletis Pharma Inc. is headquartered in Hangzhou, People's Republic of China.

Open Ascletis Pharma Inc. (ASCLF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.